



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

December 20, 2019

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Press Release

Enclosed is a press release issued by the Company confirming that reports appearing in some sections of the media indicating that its brand Rantac® (Ranitidine molecule) has been banned, is false and incorrect.

Kindly take the same on record.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
📞 +91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Press Release

J. B. Chemicals clears the confusion around Rantac® (Ranitidine)

In a statement issued today, **J. B. Chemicals and Pharmaceuticals Limited (JBCPL)** said that reports appearing in some sections of the media indicating that their brand Rantac® (Ranitidine molecule) has been banned, is false and incorrect. There has also been a lot of social media conversations that have misled the public, some section of the press, and even healthcare professionals.

Ranitidine recently drew the attention of the Healthcare industry, Regulatory bodies and the Media after excess levels of NDMA (N Nitrosodimethylamine) were found in some of the Ranitidine products in USA. NDMA is an environmental impurity which is also found in drinking water, food, including meat(s), dairy products, and vegetables.^{1,2}

The company would like to categorically assert that their product Rantac® is not banned by the regulatory authorities. As a responsible manufacturer, JBCPL continues to manufacture Rantac® which complies with all the standards set by the Drug Controller General of India (DCG(I)).

Mr. Savya Sachi-President, Sales & Marketing, JBCPL, said,

"Incomplete and inaccurate reporting in some sections of the media has led to considerable confusion in the minds of Public, Pharmacists and Healthcare Professionals about Ranitidine, NDMA and possible relationship with cancer. Our product Rantac® has been available in the Indian market as a safe medicine for acidity related disorders for 30 years. We will continue to make and sell/market Rantac® in accordance with set standards."

Dr Ashish Birla-General Manager, Medical Affairs, JBCPL, said,

"Rantac® which was introduced in 1985 has stood up to the expectations of the medical fraternity for being safe and efficacious. Ranitidine is on the World Health Organization's List of Essential Medicines.³ At JBCPL, patient safety is a core value; so we take every possible measure to ensure that our medicines are safe for human consumption."

1. *Journal of Water and Health* 2007; 5(3): 341-355.
2. *J. Assoc. Off. Anal. Chem.* 1981; 64(5), 1238-1242.
3. https://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

About J. B. Chemicals and Pharmaceuticals Limited (JBCPL)

Established in 1976, J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India's fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally. Today, JBCPL exports to over 30 countries across the world and earns more than half its revenue from its international business. JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. JBCPL has its headquarters in India's financial capital, Mumbai. With a domestic sales force of 2000 people, several internationally approved State-of-the-Art manufacturing units, a Research and Development Centre, and subsidiaries abroad, the organisation is continually enhancing value for its shareholders. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380